person · Reporting owner
Sollie-Zetlmayer Hege Elisabeth
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | Director | July 28, 2026 | July 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,526 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Grant · Acquired 4,000 · Balance 50,526 F1: Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting in three equal annual installments, commencing on July 28, 2027. Row 2 · 2026-07-28 · Grant · Acquired 2,000 · Balance 52,526 F2: Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting on January 2, 2027. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.39 · Expires 2036-07-27 | Direct | 3,475 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Grant · Acquired 3,475 · Balance 3,475 F3: This option was granted on July 28, 2026 and vests over 36 equal monthly installments, commencing on August 28, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $75.39 · Expires 2036-07-27 | Direct | 1,738 |
Reported balance
After 2026-07-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-28 · Grant · Acquired 1,738 · Balance 1,738 F4: This option was granted on July 28, 2026 and vests over six equal monthly installments, commencing on August 2, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting in three equal annual installments, commencing on July 28, 2027.
F2: Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting on January 2, 2027.
F3: This option was granted on July 28, 2026 and vests over 36 equal monthly installments, commencing on August 28, 2026.
F4: This option was granted on July 28, 2026 and vests over six equal monthly installments, commencing on August 2, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 31, 2026 01:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 1,738 | $0.00 Strike: $75.39 | $0.00 |
DisclosureSEC source: 0002142653-26-000004 · form4-07312026_010711.xml · derivative · entry 4 Sollie-Zetlmayer Hege Elisabeth · CIK 0002142653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,738 Underlying: Common Stock · 1,738 shares Expires 2036-07-27 F4 · kind: This option was granted on July 28, 2026 and vests over six equal monthly installments, commencing on August 2, 2026. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 01:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 3,475 | $0.00 Strike: $75.39 | $0.00 |
DisclosureSEC source: 0002142653-26-000004 · form4-07312026_010711.xml · derivative · entry 3 Sollie-Zetlmayer Hege Elisabeth · CIK 0002142653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,475 Underlying: Common Stock · 3,475 shares Expires 2036-07-27 F3 · kind: This option was granted on July 28, 2026 and vests over 36 equal monthly installments, commencing on August 28, 2026. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 01:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002142653-26-000004 · form4-07312026_010711.xml · nonDerivative · entry 2 Sollie-Zetlmayer Hege Elisabeth · CIK 0002142653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,526 F2 · kind: Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting on January 2, 2027. Read SEC document |
| July 28, 2026 Filed Jul 31, 2026 01:02 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0002142653-26-000004 · form4-07312026_010711.xml · nonDerivative · entry 1 Sollie-Zetlmayer Hege Elisabeth · CIK 0002142653 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,526 F1 · kind: Restricted stock units granted on July 28, 2026, with the shares underlying such restricted stock units vesting in three equal annual installments, commencing on July 28, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.